格隆汇2月23日｜诺和诺德股价下跌13%，跌至2021年6月以来最低水平。消息面上，诺和诺德减肥药在 CagriSema试验中效果不及礼来。 ...

每经AI快讯，2月23日，礼来美股盘前涨2.6%，消息面上，诺和诺德减肥药在CagriSema试验中效果不 及礼来。 ...

Core Viewpoint - The announcement from Baili Tianheng indicates that its drug, iza-bren (EGFR×HER3 dual antibody ADC), has successfully met its primary endpoints in a Phase III clinical trial for locally advanced or metastatic triple-negative breast cancer, marking a significant milestone in the treatment of this condition [1] Group 1: Clinical Trial Results - The top-line data shows that iza-bren significantly extends progression-free survival (PFS) and overall survival (OS), achieving dual primary endpoints [1] - This is the third Phase III clinical study where the dual antibody ADC has reached its primary endpoints, and it is the first dual antibody ADC globally to achieve positive PFS/OS results in the treatment of triple-negative breast cancer [1] Group 2: Regulatory Status - As of now, iza-bren has seven indications included in the breakthrough therapy list by the National Medical Products Administration (NMPA) in China, and one indication included by the U.S. Food and Drug Administration (FDA) [1] - Two indications for iza-bren, targeting locally advanced or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, have had their market applications accepted by the NMPA and are included in the priority review process [1]

Core Viewpoint - Bailitianheng (688506.SH) announced that its drug iza-bren (EGFR×HER3 bispecific antibody ADC) has achieved the primary endpoint in a Phase III clinical trial for locally advanced or metastatic triple-negative breast cancer [1] Group 1: Clinical Trial Results - The independent data monitoring committee (iDMC) recommended early communication with regulators based on the interim analysis results while continuing to follow up with participants [1] - Topline data indicates that iza-bren significantly extended progression-free survival (PFS) and overall survival (OS), achieving dual primary endpoints [1] - This Phase III clinical trial is the third to reach primary endpoints for the bispecific antibody ADC and is the first globally to achieve positive PFS/OS results in triple-negative breast cancer treatment [1]

Core Viewpoint - The announcement from Baillie Gifford (688506.SH) indicates that the mid-term analysis of the Phase III clinical trial for iza-bren (EGFR×HER3 bispecific ADC) has met its primary endpoints, suggesting early regulatory submission while continuing patient follow-up [1] Group 1: Clinical Trial Results - The independent data monitoring committee (iDMC) recommended early regulatory communication based on the current analysis results [1] - Topline data shows that iza-bren significantly extends progression-free survival (PFS) and overall survival (OS), achieving dual primary endpoints [1] - This Phase III clinical trial is the third to achieve primary endpoints for this bispecific ADC and is the first globally to report positive PFS/OS results in triple-negative breast cancer treatment [1]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

整理 | GLP1减重宝典内容团队 近年来，司美格鲁肽作为一种新型减肥药物在全球范围内引起了广泛关注。这款由丹麦诺和诺德公司研发的胰高血糖素样肽-1（GLP-1）受体 激动剂，以其简便的减肥方式改变了人们对于体重管理的认知。 司美格鲁肽通过促进胰岛素分泌、抑制胰高血糖素分泌、延缓胃排空以及增加饱腹感，抑制下丘脑摄食中枢的作用而抑制食欲，实现降糖和减 重的双重效果。 ▍ 司美格鲁肽的减重效果 临床数据表明，司美格鲁肽的减重效果显著。 经过68.1周的连续注射，患者平均体重下降了15%，中位数体重减轻达到15.3千克。 《柳叶刀-糖尿病与内分泌学》杂志发表的一项国内研究也显示，每周注射2.4mg司美格鲁肽的患者，在44周后体重下降了12.1%，而安慰剂组 仅下降了3.6%。 此外，Wegovy（司美格鲁肽的商品名）治疗能够使超重或肥胖成人患者体重减轻效果持续超过65周，并可维持长达4年。在208周时，Wegovy 组患者的平均体重下降了10.2%，腰围减少了7.7cm，腰高比下降了6.9%，而安慰剂组的相应数据分别为1.5%、1.3cm和1.0%。 ▍ 司美格鲁肽的安全性 司美格鲁肽的副作用主要表现为初期的胃肠道 ...

阅读须知：本文所有信息与数据均来源于作者查阅的官方资料和网络信息的整合，旨在为读者提供更清晰的视角。如果有数据或观点错误，欢迎文明评论， 作者会积极改正！创作不易，文章需要查阅多方资料、整合分析与总结，望大家理解。 最近看到一位印度教授信誓旦旦地说，2026年印度制造业将全面超越中国时，我的第一反应不是愤怒，而是好奇。好奇的并不是他敢说得这么猛烈，而是他 究竟凭什么这么说。这类言论，近几年在印度并不少见。GDP增长迅猛、人口红利、地缘政治优势，再加上全球产业链重构的趋势，这一切的叠加让很多人 产生了战略上的幻觉，但制造业从来不是依靠空洞的口号就能赢得胜利的。 根据协力管理咨询发布的2026年亚洲制造业指数，报告显示，在对11个亚洲经济体从经济体量、营商环境、基础设施、劳动力、供应链等八个维度进行综合 评估后，结果非常明确：中国依然排名第一，而印度则停留在第六位，与去年持平——注意，是止步第六，而不是暂列第二。问题来了，为什么一边是教授 的豪言壮语，一边却是冷静无情的排名数据？这种反差背后，究竟是什么原因呢？ 关键在于，印度把潜力当成了实力。我们不得不承认，印度确实拥有一些优势。报告中明确指出，印度的优势主要体 ...

14,000 16,000 18,000 20,000 22,000 24,000 26,000 28,000 30,000 | 26705.94 | 0.52 | 4.20 | | --- | --- | --- | | 9070.32 | 0.42 | 1.76 | | 5367.52 | 0.13 | -2.69 | | 116.21 | -1.03 | -5.87 | | 4082.07 | -1.26 | 2.85 | | 14100.19 | -1.28 | 4.25 | | 4660.41 | -1.25 | 0.66 | | 49395.16 | -0.54 | 2.77 | | 22682.73 | -0.31 | -2.41 | | 6861.89 | -0.28 | 0.24 | | 25043.57 | -0.93 | 2.26 | | 8398.78 | -0.36 | 3.06 | | 10627.04 | -0.55 | 7.00 | 2026年2月20日星期五 ➢ 美重兵集结中东；美国暂搁置重大对台 军售。A股休市。上证指数收跌1.26%报 4082.07点，深证成指跌1.28 ...

智通财经APP讯，基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用 品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或 ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌 (NSCLC)成人患者。 基石药业首席医学官史青梅博士表示："此次MHRA对舒格利单抗III期NSCLC新适应症的批准是国际监 管机构对其临床价值的进一步肯定，将有力助推该产品的全球商业潜力释放。同时，我们也为基石药业 临床开发和注册团队高效的执行力、宝贵的全球注册经验以及成功适应欧洲与英国成熟监管体系的能力 而深感自豪。目前，舒格利单抗联合化疗用于IV期NSCLC已获《欧洲肿瘤内科学会(ESMO)非驱动基因 阳性转移性非小细胞肺癌动态临床指南》最高等级【I, A】的一线治疗推荐，我们期待其III期NSCLC新 适应症在不久的将来也能获得该权威指南推荐。此外，基石药业还将推进舒格利单抗用于胃癌(GC)、 食管鳞癌(ESCC)等新适应症的注册申报。" 基石药业首席执行官、研发总裁及执行董事杨建新博士表示： ...